The Long-HER Study

Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. Some of these patients may become long-term survivors. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression to trastuzumab.

53

Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López-Vacas R, Berges-Soria J, López IÁ, Margeli M, Calero JL, Farre XG, Santaballa A, Ciruelos EM, Afonso R, Lao J, Catalán G, Gallego JV, López JM, Bofill FJ, Borrego MR, Espinosa E, Vara JA, Zamora P